RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06928389, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed diagnosis of NSCLC.

    Inclusion criterion 5

  3. Locally advanced or metastatic NSCLC (American Joint Committee on Cancer [AJCC] 8th edition).

    Inclusion criterion 6

  4. Previously received systemic platinum-based chemotherapy and PD-1/L1 inhibitors.

    Inclusion criterion 7

    Prior administration of any immunotherapy targeting immune mechanisms other than PD-1/PD-L1 inhibitors.

    Exclusion criterion 4

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    Inclusion criterion 3

  6. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

    Inclusion criterion 8

  7. Other malignancies within 3 years prior to randomization.

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06928389, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).
  • Age ≥ 18 years old and ≤ 75 years old at the time of randomization.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Expected life expectancy of at least 3 months.
  • Histologically or cytologically confirmed diagnosis of NSCLC.
  • Locally advanced or metastatic NSCLC (American Joint Committee on Cancer [AJCC] 8th edition).
  • Previously received systemic platinum-based chemotherapy and PD-1/L1 inhibitors.
  • At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
  • Adequate organ function.

Exclusion Criteria:

  • Histologic or cytopathologic evidence of the presence of small cell lung carcinoma.
  • Other malignancies within 3 years prior to randomization.
  • Known actionable genomic alterations.
  • Prior administration of any immunotherapy targeting immune mechanisms other than PD-1/PD-L1 inhibitors.
  • Previous treatment with docetaxel.
  • History of severe bleeding tendency or coagulation dysfunction.
  • Active autoimmune disease requiring systemic therapy within 2 years prior to randomization.
  • History of myocarditis, cardiomyopathy, and malignant arrhythmia.

Quoted from ClinicalTrials.gov, NCT06928389, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06928389, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06928389